SMC backs five new medicines for NHS use
Servier’s Lonsurf and AstraZeneca’s Calquence are among the positive decisions
Read More
Tag: Lonsurf
Six new medicines accepted for NHS use in Scotland
Cost regulators for NHS treatments in Scotland have backed six medicines offering new options to some patients with cancer, chronic migraine, high cholesterol and iron deficiency.
Read More
Servier’s Lonsurf backed for NHS use
Patients with advanced bowel cancer in England and Wales stand to gain routine access to a new treatment option after cost regulators backed NHS funding for Servier’s Lonsurf.
Read More
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
